124 related articles for article (PubMed ID: 38899786)
1. The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
Jairath V; Rubin DT; Verstockt B; Çekin AH; Abreu MT; Lees CW; Fellmann M; Woolcott JC; Crosby C; Wu J; Bhattacharjee A; Herman D; Gu G; Siegmund B
Inflamm Bowel Dis; 2024 Jun; ():. PubMed ID: 38899786
[TBL] [Abstract][Full Text] [Related]
2. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial.
Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
J Crohns Colitis; 2024 Jun; 18(6):885-894. PubMed ID: 38245818
[TBL] [Abstract][Full Text] [Related]
3. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L; Dubinsky MC; Sands BE; Panés J; Schreiber S; Reinisch W; Feagan BG; Danese S; Yarur AJ; D'Haens GR; Goetsch M; Wosik K; Keating M; Lazin K; Wu J; Modesto I; McDonnell A; Bartolome L; Vermeire S
J Crohns Colitis; 2024 Apr; ():. PubMed ID: 38613425
[TBL] [Abstract][Full Text] [Related]
5. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Vermeire S; Sands BE; Peyrin-Biroulet L; D'Haens GR; Panés J; Yarur AJ; Wolf DC; Ritter T; Schreiber S; Woolcott JC; Modesto I; Keating M; Shan K; Wu J; Chiorean MV; Baert F; Dubinsky MC; Goetsch M; Danese S; Feagan BG
J Crohns Colitis; 2024 Jun; ():. PubMed ID: 38877972
[TBL] [Abstract][Full Text] [Related]
6. Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events From the ELEVATE UC Clinical Program.
Regueiro M; Siegmund B; Yarur AJ; Steinwurz F; Gecse KB; Goetsch M; Bhattacharjee A; Wu J; Green J; McDonnell A; Crosby C; Lazin K; Branquinho D; Modesto I; Abreu MT
J Crohns Colitis; 2024 May; ():. PubMed ID: 38700040
[TBL] [Abstract][Full Text] [Related]
7. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
Choi D; Becker M; Ivanov M; Bhat S
Ann Pharmacother; 2024 Jan; ():10600280231225770. PubMed ID: 38258760
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
[TBL] [Abstract][Full Text] [Related]
9. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
Vermeire S; Chiorean M; Panés J; Peyrin-Biroulet L; Zhang J; Sands BE; Lazin K; Klassen P; Naik SU; Cabell CH; Sandborn WJ
J Crohns Colitis; 2021 Jun; 15(6):950-959. PubMed ID: 33475734
[TBL] [Abstract][Full Text] [Related]
10. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis.
Walsh A; Kormilitzin A; Hinds C; Sexton V; Brain O; Keshav S; Uhlig H; Geddes J; Goodwin G; Peters M; Collins G; Travis S
J Crohns Colitis; 2019 Mar; 13(4):424-430. PubMed ID: 30445625
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.
Takashima S; Kato J; Hiraoka S; Nakarai A; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H; Tanaka T; Yamamoto K
Am J Gastroenterol; 2015 Jun; 110(6):873-80. PubMed ID: 25823769
[TBL] [Abstract][Full Text] [Related]
12. Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease.
Boschetti G; Laidet M; Moussata D; Stefanescu C; Roblin X; Phelip G; Cotte E; Passot G; Francois Y; Drai J; Del Tedesco E; Bouhnik Y; Flourie B; Nancey S
Am J Gastroenterol; 2015 Jun; 110(6):865-72. PubMed ID: 25781366
[TBL] [Abstract][Full Text] [Related]
13. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
[TBL] [Abstract][Full Text] [Related]
14. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces.
Hiraoka S; Takashima S; Inokuchi T; Nakarai A; Takahara M; Harada K; Seki Y; Watanabe K; Kato J; Okada H
Intest Res; 2019 Apr; 17(2):202-209. PubMed ID: 30541228
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis.
Ryu DG; Kim HW; Park SB; Kang DH; Choi CW; Kim SJ; Nam HS
Medicine (Baltimore); 2019 Sep; 98(36):e17080. PubMed ID: 31490411
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).
Silverberg JI; Bissonnette R; Kircik L; Murrell DF; Selfridge A; Liu K; Ahluwalia G; Guttman-Yassky E
J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):1366-1374. PubMed ID: 36695074
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis.
Stevens TW; Gecse K; Turner JR; de Hertogh G; Rubin DT; D'Haens GR
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2333-2342. PubMed ID: 32801008
[TBL] [Abstract][Full Text] [Related]
18. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
[TBL] [Abstract][Full Text] [Related]
19. Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease.
Abedin N; Seemann T; Kleinfeld S; Ruehrup J; Röseler S; Trautwein C; Streetz K; Sellge G
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31756948
[TBL] [Abstract][Full Text] [Related]
20. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
